Medicare Part D Plans May Add ‘Preferred' Specialty Tiers To Lower Costs
(2/6, Cathy Kelly, Pink Sheet) reports “...[CMS] is proposing to allow Medicare Advantage and Medicare Part D plans to add a second, ‘preferred’ specialty drug formulary tier with lower cost sharing beginning in 2021 as a way to ‘enhance’ price negotiations with manufacturers and promote the use of lower-cost biosimilars...[T]he change could ‘improve the ability of Part D sponsors and pharmacy benefit managers to negotiate better rebates with manufacturers by enabling them to establish a preferred … tier that would distinguish between high-cost drugs and effectively encourages the use’ of lower cost agents, the proposal notes.” Paid Subscription Required
Video: Using Real-World Evidence to Compare DOACs for Stroke Prevention in Patients With NVAF
(2/7, PeerView CME) “Chair, Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC discusses nonvalvular atrial fibrillation in this CME/MOC/CNE/CPE activity titled ‘Demystifying the Real-World Evidence in Atrial Fibrillation: A Comparative Look at the Direct Oral Anticoagulants for Reducing the Risk of Stroke Among Patients With Nonvalvular Atrial Fibrillation.’” View Video
How Independent Assessment of Drug Value Can Help States
(2/7, Steve D. Pearson and Sarah K. Emond, ICER Blog) comments “...Ultimately, independent drug value reports provide the fair benchmark by which to gauge the reasonableness of prices that drug manufacturers set and often increase unilaterally, with limited or no justification. As policymakers experiment with transparency initiatives, bulk purchasing programs, and/or new legal guidelines, independent drug value reports can help determine how effective those initiatives have been in bringing drug prices more in line with the benefit they deliver to patients.” Full
Mass. Outlines Deal For A $2 Million Drug: Pay Only If It Works
(2/7, Martha Bebinger, WBUR) reports “...MassHealth will pay slightly less than $2 million for each Zolgensma infusion...State payments, evaluations and refunds if the drug is not effective would stretch over five years. Novartis routinely offers a five-year payment plan for Zolgensma. The company said in a statement that these so-called value-based or outcomes-based agreements are becoming routine as well. It says it is in ‘active discussions’ with Massachusetts.” Full
Does the Use of Health Technology Assessment Have an Impact on the Utilisation of Health Care Resources? Evidence from Two European Countries
Corbacho B, et al.
February 5, 2020, The European Journal of Health Economics
Patients, Clinicians and Researchers Working Together to Improve Cardiovascular Health: A Qualitative Study of Barriers and Priorities for Patient-Oriented Research
Maria-Jose Santana, et al.
February 6, 2020, BMJ Open